Compounded tirzepatide FDA status: dated 2026 update
What FDA has actually decided about compounded tirzepatide, what is only proposed, and what each item means if you are buying it. Every status carries a date.
Compounded tirzepatide is not FDA-approved and never has been. FDA declared the tirzepatide shortage resolved on December 19, 2024, and the shortage-based allowances for compounders ended in February (503A) and March (503B) 2025. Patient-specific compounding continues only under conditions FDA has kept tightening, including a 2026 proposal to remove tirzepatide from the 503B bulks list. Every status below is dated; verify before relying on it.
Status at a glance (checked August 26, 2026)
| Question | Status | What it rests on |
|---|---|---|
| Is compounded tirzepatide FDA-approved? | No. No compounded drug is. | FDA reviews approval applications for specific products (Zepbound®, Mounjaro®). Compounded preparations are exempt from that review and are not evaluated for safety, effectiveness or quality before sale (FDA: compounding and the FDA — questions and answers). |
| Is tirzepatide on the FDA shortage list? | No — resolved December 19, 2024. | FDA: policies for compounders as national GLP-1 supply begins to stabilize; live status: FDA Drug Shortages database. |
| Can a 503A pharmacy still compound it? | Only under the ordinary 503A conditions, not the shortage exception. | 503A requires a valid patient-specific prescription and prohibits compounding what is “essentially a copy” of an available approved drug except where a prescriber documents a significant clinical difference for that patient. Whether a given product meets that test is a fact question FDA and state boards can contest. |
| Can a 503B outsourcing facility still compound it? | Conditionally, and under review. | 503B facilities may compound from bulk substance only for drugs on the 503B bulks list (or pending on it) or on the shortage list. FDA has proposed removing tirzepatide from the bulks list (FDA press announcement: proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list). Check whether that proposal has been finalized. |
| Did FDA “ban” compounded tirzepatide? | No formal ban. The shortage-based pathway ended; enforcement targets non-compliant products and claims. | FDA: concerns with unapproved GLP-1 drugs used for weight loss |
| Is it legal in my state? | Depends on state law and the pharmacy’s licensure for your state. | State boards of pharmacy license the dispensing pharmacy and may restrict shipping into the state. Verify the pharmacy through your state board (NABP directory of state boards of pharmacy). |
Timeline of federal actions
| Date | What happened | Status |
|---|---|---|
| Dec 2022 | FDA adds tirzepatide (Mounjaro) to the drug shortages list. While a drug is on the list, sections 503A and 503B permit compounders to prepare versions of it under FDA’s shortage policies. | Historical |
| Oct 2, 2024 | FDA announces the tirzepatide shortage is resolved. The Outsourcing Facilities Association sues; FDA agrees to re-evaluate and to pause enforcement while it does. | Historical |
| Dec 19, 2024 | FDA confirms the resolution and publishes an enforcement timeline: it would not take action against 503A pharmacies compounding tirzepatide until February 18, 2025, or against 503B outsourcing facilities until March 19, 2025. | Final |
| Feb 21, 2025 | FDA declares the semaglutide shortage resolved (503A grace until April 22, 2025; 503B until May 22, 2025). Relevant because most telehealth programs offer both drugs. | Final |
| Mar–Nov 2025 | Federal court rulings decline to block FDA’s shortage decisions. FDA issues warning and untitled letters to telehealth companies and pharmacies over promotional claims for compounded GLP-1s, including claims that imply FDA approval, and publishes its running “concerns with unapproved GLP-1 drugs” notice (dosing errors, salt forms, unapproved additives, sterility). | Final / ongoing |
| 2026 | FDA publishes a proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. If finalized, 503B outsourcing facilities could no longer compound tirzepatide from bulk drug substance. As of our last check this was a proposal, not a final decision. | Proposed — verify current status |
What this means for patients
- A prescription is mandatory. Any seller offering tirzepatide without a clinician evaluation is outside every lawful pathway. “Research use only” vials are not medicine.
- The pharmacy matters more than the website. Ask which pharmacy fills your prescription, whether it is a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, and verify it (how to verify a pharmacy, 503A vs 503B explained).
- Supply can change with a single FDA decision. A finalized bulks-list exclusion would affect 503B-sourced products first. Providers that use 503A pharmacies, or that can move patients between pharmacies, are less exposed. Ask your provider what happens to your plan if its pharmacy can no longer compound tirzepatide.
- Marketing language is regulated too. FDA has objected to claims that compounded GLP-1s are “FDA-approved”, “the same as” the brand, or proven by the brand’s trials. Treat those phrases as red flags.
- Prepaid plans carry regulatory risk. Before prepaying 6–12 months, confirm in writing what the provider refunds if compounding of tirzepatide is curtailed (what to do if you need to switch).
Proposed vs final: why the distinction matters
News coverage often reports a proposal as if it were in force. A proposed FDA action (a notice, a draft guidance, a proposed rule, or a bulks-list proposal) invites comment and can be withdrawn or changed; a final action has a stated effective date and an enforcement position. Our status table names which is which. When a proposal is finalized we update the table the same day we confirm it and add a change-log entry below.
Frequently asked questions
It can be lawfully prescribed and dispensed only when the specific conditions of section 503A (or, while permitted, 503B) and state law are met — a patient-specific prescription from a licensed clinician, a pharmacy licensed for your state, and no claim to be a copy of the approved product beyond what the prescriber has documented. It is not FDA-approved. Because the federal position keeps moving, check the dated status table above rather than relying on a yes/no answer.
There is no formal ban. FDA ended the shortage-based allowance in early 2025 and has since acted against products and marketing it considers unlawful. Its 2026 proposal to remove tirzepatide from the 503B bulks list would, if finalized, stop bulk compounding by 503B facilities but would not by itself change patient-specific 503A compounding.
If your medication comes from a 503B outsourcing facility and the proposal is finalized, that facility would have to stop compounding tirzepatide from bulk substance. Ask your provider which pathway your pharmacy uses and what its contingency is. If your medication comes from a 503A pharmacy, the proposal does not directly apply.
No. It is neither. FDA has sent warning letters over exactly these claims. A generic drug is an FDA-approved product shown to be equivalent to a brand; a compounded preparation has not been reviewed by FDA at all.
The four FDA pages listed under Primary sources, plus your state board of pharmacy. We link them so you can confirm anything on this page in a few minutes.
Primary sources
- FDA: policies for compounders as national GLP-1 supply begins to stabilize
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- FDA press announcement: proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
- FDA: compounding and the FDA — questions and answers
- FDA Drug Shortages database
- NABP directory of state boards of pharmacy
Change log
Substantive changes to this page are logged so readers and AI systems can judge how current it is.
| Date | Change |
|---|---|
| August 26, 2026 | Page created as the dated regulatory status hub, replacing the July 2026 “shutdown tracker” guide. Categorical “still legal” wording replaced with pathway-specific, dated status. Bulks-list proposal recorded as proposed pending confirmation. |
Legal review: completed before publication (August 26, 2026); the page is re-reviewed on every status change. Educational information only; not legal or medical advice.